

Day 1 - Friday, 8 April, 2011										
1330 – 1335	Opening address Emma GRAINGER (UK)									
1335 – 1340	Welcome address by local organizing committee									
	Opening Plenaries Moderator: Emma GRAINGER (UK)									
1340 – 1405	Cancer Control in Asia – A look at the future Judith MACKAY (Hong Kong)									
1405 – 1430	Work of GAPRI and the importance of pain relief - An Asian perspective Meg O'BRIEN (USA)									
1435 – 1515	Tea Symposium									
1515 – 1545	Tea Break Exhibition & Networking									
	Pleinary Session									
1545 – 1610	IGFR inhibitors in paediatric and adult sarcomas Robert MAKI (USA)									
1610 – 1635	Isolated Limb Perfusion For limb threatening tumors Alexander M. M. EGGERMONT (France)									
1635 – 1650	Q & A									
End of Day 1										
Day 2 - Saturday, 9 April, 2011										
	Gastrointestinal Cancer Suite Chair: CHENG Ann-Lii (Taiwan)	Women's Health Suite Chair: Masakazu TOI (Japan)	Haematology-Oncology Chair: KWONG Yok Lam (HK)	Thoracic Cancer Chair: Masahiro FUKUOKA (Japan)	Radiation Oncology Chair: Werner BURKART (Austria)					
	GI Symposium 1 Moderators: Robert MAKI (USA), Yoon-Koo KANG (Korea)	WH Symposium 1 Moderator: Ikuo KONISHI (Japan)	HO Symposium 1 Moderators: Yok Lam KWONG (Hong Kong), Soon Thye LIM (Singapore)	TC Symposium 1 Moderator: Darren LIM (Singapore)	RO Symposium 1 Moderator: Rethy CHHEM (Austria)					
0845 – 0910	Adjuvant treatment of resected localized GIST Yoon-Koo KANG (Korea)	Natural history of ovarian cancer development: Its early detection or screening feasible? Ikuo KONISHI (Japan)	Recent advances in the treatment of aggressive B cell lymphomas Michael PFREUNDSCHUH (Germany)	Current status and future perspectives of LDCT screening for early lung cancer – An Asian aspect Kenji EGUCHI (Japan)	Radiation induced thyroid carcinoma Shunichi YAMASHITA (Japan)					
0910 – 0935	Recent advances in surgical treatment of gastric cancer Chiu-Wen WU (Taiwan)	Cervical Cancer Prevention: Asian Context Sarikapan WILAILAK (Thailand)	Natural killer cell lymphoma: diagnosis and treatment KWONG Yok Lam (Hong Kong)	Management of patients with locally advanced NSCLC Masahiro FUKUOKA (Japan)	Interventional radiology treatment of liver cancer – An algorithmic approach Shi-Chang WANG (Australia)					
0935 – 1000	Targeting therapy for metastatic gastric cancer Li JIN (China)	Current treatment modality for gynecological cancer Chyong Huey LAI	Management of T-cell lymphoma LIM Soon Thye (Singapore)	Maintenance therapy in Asian NSCLC patients Sang-We KIM (Korea)	Temporal lobe necrosis following radiotherapy for nasopharyngeal carcinoma					

		(Taiwan)			Stephen Chun-Key LAW (Hong Kong)
1000 – 1010	Q&A	Q&A	Q&A	Q&A	Q&A
1015 – 1100	Tea Symposium				
1100 – 1120	Tea Break Exhibition & Networking				
	Gastrointestinal Cancer Suite	Women's Health Suite	Haematology-Oncology	Thoracic Cancer	Radiation Oncology
	GI Symposium 2 Moderators: <b>CHENG Ann-Lii</b> (Taiwan), Jordi BRUIX (Spain)	WH Symposium 2 Moderator: <b>Hyun Cheol CHUNG</b> (Korea)	HO Symposium 2 Moderators: <b>Hwei-Fang TIEN</b> (Taiwan), Bin Tean TEH (Singapore)	TC Symposium 2 Moderator: <b>Masahiro FUKUOKA</b> (Japan)	RO Symposium 2 Moderator: <b>Shih-Chang WANG</b> (Australia)
1120 – 1145	Multimodality treatment for oesophageal cancer <b>Jong-Hoon KIM</b> (Korea)	Targeted treatment for metastatic breast cancer <b>Hyun Cheol CHUNG</b> (Korea)	Targeting therapy from acute promyelocytic leukemia to acute myeloid leukaemia with t(8;21) <b>Saijuan CHEN</b> (China)	Treatment for EGFR-TKI sensitive and resistant NSCLC <b>Darren LIM</b> (Singapore)	The role of interventional radiology in the management of malignant biliary obstruction <b>TAN Bien Soo</b> (Singapore)
1145 – 1210	Future perspective of systemic treatment for hepatocellular carcinoma <b>Ann Lii CHENG</b> (Taiwan)	Sentinel node biopsy in early breast cancer: unanswered questions and future management <b>Norman WOLMARK</b> (USA)	Genomic profiling of T-cell lymphoma <b>Bin Tean TEH</b> (Singapore)	Targeted therapy in advanced NSCLC: beyond EGFR-TKI <b>Lu SHUN</b> (China)	Radiotherapy for uterine cervical cancer including the result of multicenter study in Asia <b>Shingo KATO</b> (Japan)
1210 – 1235	Staging system for HCC and the value of evidence-based guidelines <b>Jordi Bruix</b> (Spain)	Application of biomarkers to sentinel lymph node biopsy for the management of breast cancer <b>Louis CHOW</b> (Hong Kong)	Genetic alterations in acute myeloid leukemias and the clinical implications <b>Hwei-Fang TIEN</b> (Taiwan)	Radical management of patients with lung cancer <b>Eric LIM</b> (UK)	The role of radiotherapy in haematological malignancies – Is there any? <b>Susan LOONG</b> (Singapore)
1235 – 1245	Q&A	Q&A	Q&A	Q&A	Q&A
1300 – 1400	Lunch Symposium				
	Gastrointestinal Cancer Suite	Women's Health Suite	Genitourinary Cancer Suite Chair: Brian RINI (USA)	Head & Neck Cancer Chair: Anthony CHAN (HK)	Radiation Oncology
	GI Symposium 3 Moderator: <b>Yoshiharu MOTOO</b> (Japan)	WH Symposium 3 Moderator: <b>Masakazu TOI</b> (Japan)	GU Symposium 1	HN Symposium 1 Moderator: <b>Anthony CHAN</b> (HK)	RO Symposium 3 Moderator: <b>Bien Soo TAN</b> (Singapore)
1415 – 1440	Chemotherapy for	Neoadjuvant	Hypertension and	Systemic therapy	Atoms for health:

	pancreatic cancer: molecular analysis and clinical application <b>Yoshiharu MOTOO</b> (Japan)	therapy for breast cancer. Incorporation of new agents and exploration of predictive biomarkers <b>Masakazu TOI</b> (Japan)	other Biomarkers of Response in Metastatic RCC <b>Brain RINI</b> (USA)	(including chemotherapy and targeted therapies) <b>Anthony CHAN</b> (Hong Kong)	Radiation medicine to all <b>Werner BURKART</b> (Austria)					
1440 – 1505	Ruihua XU (China)	Latest developments in ovarian cancer: Available agents and a view to the future <b>Eric PUJADE-LAURAIN</b> (France)	Advanced radiation techniques for prostate cancer <b>Andrew K LEE</b> (USA)	Recent advances in radiotherapy for head and neck cancers <b>Joseph WEE</b> (Singapore)	Nuclear science and technology against cancer: The IAEA global role <b>Rethy CHHEM</b> (Austria)					
1505 – 1530	Biomarkers in colon cancer: what we have now and what lies ahead <b>LIM Hwee Yong</b> (Singapore)	Use of genomics in breast cancer diagnosis and management <b>LEE Soo Chin</b> (Singapore)	<i>Bladder Cancer</i>	Recent advances in translational research <b>Alex Pei-Jen LOU</b> (Taiwan)	SBRT in the treatment body tumors using CyberKnife system <b>Chul Koo CHO</b> (Korea)					
1530 – 1545	Q&A	Q&A	Q&A	Q&A	Q&A					
1545 – 1630	Tea Symposium									
1630 – 1700	Tea Break Exhibition & Networking									
	The Lancet Oncology Editor's Choice Poster Awards: Oral Presentations 1 Moderator: Emma GRAINGER (UK)									
1700 – 1705	Introduction									
1705 – 1712	adherence to 6-month oral alpha lipoic acid for prevention of platinum-induced polyneuropathy <b>Y GUO</b> (USA)									
1713 – 1720	Nab-paclitaxel in the treatment of advanced pancreatic cancer refractory to gemcitabine—final results of a phase 2 trial <b>Gilberto de Lima Lopes</b> (Singapore)									
1721 – 1728	cost-effectiveness of epidermal growth-factor receptor mutation testing and first-line treatment with gefitinib for advanced non-small-cell lung cancer <b>Gilberto de Lima Lopes</b> (Singapore)									
1729 – 1736	salvage chemotherapy in primary resistant or relapsing stage III–IV neuroblastoma <b>H.A SAYED</b> (Egypt)									
1737 – 1744	difference in hormone-receptor status of breast cancers in Vietnamese and Swedish women <b>Thang VU HONG</b> (Vietnam)									
1745 – 1752	clinical significance of down-regulated SPARCL1 in human gastric cancer <b>Ping LI</b> (China)									
End of Day 2										
Day 3 - Sunday, 10 April, 2011										
	Palliative Oncology			Genitourinary Cancer						
0830 – 0900	Pain management in difficult clinical situations <b>Sebastiano MERCADANTE</b> (Italy)			The treatment of high-risk and locally-advanced prostate cancer						

		Andrew K LEE (USA)
0900 – 0930	Palliative care other than pain relief <a href="#">Jim CLEARY (USA)</a>	Current and future directions for targeted therapy in renal cell carcinoma <a href="#">Brian RINI (USA)</a>
0930 – 0945	Q&A	Q&A
	Neuro-Oncology	Supportive Oncology
0945 – 1015	Management of brain metastases using the currently available evidence <a href="#">Eric CHANG (USA)</a>	The management of mucositis <a href="#">Dorothy KEEFE (Australia)</a>
1015 – 1045	Current Management of Newly Diagnosed and Recurrent Glioblastoma Multiforme <a href="#">Michael PRADOS (USA)</a>	Anorexia cachexia syndrome <a href="#">Declan WALSH (USA)</a>
1045 – 1100	Q&A	Q&A
1100 – 1145	Tea Symposium	Tea Symposium
1145 – 1215	Tea Break Exhibition & Networking	
	<b>The Lancet Oncology</b> <b>Editor's Choice Poster Awards: Oral Presentations 2</b> Moderator : <a href="#">Emma GRAINGER (UK)</a>	
1215 – 1220	2nd Introduction	
1220 – 1227	video-assisted thoracic surgery lobectomy for non-small-cell lung cancer—propensity-score analysis based on a multi-institutional registry <a href="#">Daoyuan WANG (China)</a>	
1228 – 1235	Predictive value of CD24 and CD44 for response to neoadjuvant chemotherapy and prognosis in patients with primary breast cancer <a href="#">K Horiguchi (Japan)</a>	
1236 – 1243	Clinical utility of survivin gene expression in patients with transitional-cell carcinoma of the urinary bladder <a href="#">P. SINGH (India)</a>	
1244 – 1251	prognostic significance of F-18 FDG-PET/CT images in curatively resected gastric cancer <a href="#">JY KIM (Korea)</a>	
1252 – 1259	XPD/ERCC2 codon 751 and XRCC1 codon 280 polymorphisms and the risk of nasopharyngeal carcinoma in Malaysia <a href="#">Munn Sann LYE (Malaysia)</a>	
1300 – 1307	Nimotuzumab combined with radiotherapy for oesophageal carcinoma—a phase 2 clinical trial <a href="#">J LIANG (China)</a>	
1310 – 1325	<b>The Lancet Oncology</b> <b>Editor's Choice Poster Awards prize giving ceremony</b>	
1430 – 1630	The Lancet Oncology Writing Workshop <a href="#">Emma GRAINGER (UK)</a>	
	<b>End of AOS 2011</b>	

\*Programme is constantly being updated and subject to changes